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PBN, DMPO, AND POBN COMPOSITIONS AND 
METHOD OF USE THEREOF FOR INHIBITION 
OF AGE-ASSOCIATED OXIDATION 
This is a continuation of application Ser. No. 
07/589,177, ?led on Sep. 27, 1990, now abandoned, 
which is a continuation-in-part of US. Ser. No. 
07/422,651, entitled “Phenyl Butyl Nitrone Composi 
tions for Treatment of Oxidative Tissue Damage” ?led 
Oct. 17, 1989, by John M. Carney and Robert A. Floyd 
issued Jun. 18, 1991, as U.S. Pat. No. 5,025,032. 
BACKGROUND OF THE INVENTION 
The present invention is a method and compositions 
containing spin trapping agents for the treatment of age 
related dysfunctions and other conditions arising from 
oxidative damage. 
Age related changes in central nervous system func 
tion have generally been associated with the loss of 
cells, a widening of lateral ventricles and de?cits in 
short term memory. The precise mechanisms of func 
tional changes as a result of aging, or other diseases 
associated with aging, have not generally been agreed 
upon. 
Several mechanisms for the generation of oxidized 
material in the brain have been proposed. In particular, 
transition metals, especially iron and copper, have been 
suggested as mediating aspects of this oxidation. A 
marked reduction in certain neurotransmitter receptor 
systems has been associated with increased oxidation of 
proteins. For example, decreases in muscarinic recep 
tors and other cholinergic systems have been character 
ized as they relate to alterations in functions in Alzhei 
mers disease. It has also been hypothesized that aging is 
associated with multiple minor periods of ischemia 
(multi-infarct conditions or transient ischemia attacks) 
which, over a period of time, may give rise to the pro 
duction of oxidized protein. 
Changes associated with ischemic brain disease have 
been proposed to be the result of alterations in calcium 
disposition, increase in excitoxic neurotransmitter re 
lease, production of free radicals and the attendant aci 
dosis that results in an increase in the loosely bound 
metals in the cell that are catalytic for the generation of 
oxygen free radicals. These changes are largely limited 
to neuronal elements. Reactive gila have been demon 
strated, however, they are mostly associated with post 
neuronal damage. 
The treatment of age related dementias have been 
largely limited by the inability to develop an appropri 
ate model for the study of this condition. This is due to 
the fact that aging is a very complicated condition 
which is dif?cult to model, especially with the lack of 
speci?c information associated with the functional and 
biochemical basis of human age related dementias. The 
use of animal models has largely depended upon model 
systems used in brain studies, where the brains'are not 
truly senescent, or the use of senescent animals, with 
little understanding of the origin of the senescence or, in 
some cases, the inability to demonstrate truly functional 
senescence. 
The demonstration in a variety of systems, both neu 
ral and nonneural, that there is an age related enhance~ 
ment of the level of oxidized protein in tissue gives rise 
to the possibility that age related dysfunctions in the 
central nervous system may be associated with the 
build-up of oxidized proteins and oxidized macromole 
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cules within neurons throughout the central nervous 
system. The hypothesis is that cells which have a 
buildup of oxidized protein are less functional and less 
able to maintain the speci?ed role of those cells in that 
particular area of the central nervous system. While this 
hypothesis has been suggested by several investigators, 
there are no reports of substantial investigations in 
which alterations in the oxidized protein burden of the 
central nervous system was manipulated and correlated 
with a functional outcome on the part of the animal. 
Such an approach, if truly associated with brain dys 
function, would provide a basis for reversing the age 
related neuronal de?cit of cells that are still viable. 
Thus, such an approach is targeted at cells which are 
marginally functional but still viable. 
It is therefore the object of the present invention to 
provide composition and methods for the use in pre 
venting or reversing age related functional de?cits. 
It is further the object of the present invention to 
provide composition and methods for use thereof which 
are useful in preventing and reversing cognitive de?cits 
associated with infection or in?ammation. 
It is another object of the present invention to pro 
vide composition and methods reducing post traumatic 
cognitive dysfunction. 
SUMMARY OF THE INVENTION 
Compositions containing as the active ingredient a 
spin-trapping reagent, preferably a-phenyl butyl ni 
trone (PBN), or spin-trapping derivatives thereof, in a 
suitable pharmaceutical carrier for administration to a 
patient, are disclosed for treating or preventing symp 
toms associated with aging or other conditions, associ 
ated with oxidative tissue damage. The preferred PBN 
compositions have the following general formula: 
H 0 
C=N+ 
X Y 
wherein: 
X is phenyl or 
(0K)” 
wherein 
R is H, 
0 
ll / 
Z—C-, or Z; or —CH=N , 
\ 
Y 
and n is a whole integer from 1 to 5; or 
Y is a tert-butyl group that can be hydroxylated or 
acetylated on one or more positions; phenyl; or 
5,405,874 
Z is a C1 to C5 straight or branched alkyl group. 
Other spin-trapping agents can also be used, such as 
5,5-dimethylpyrroline-N-oxide (DMPO) or -(4-pyridyl 
l-oxide) N-tert-butyl nitrone (POBN), and other spin 
trapping derivatives thereof. 
In the preferred embodiment, the compositions are 
administered one to two times daily by oral administra 
tion, at a dosage equivalent to between one and ten 
milligrams PBN/70 kg of human body weight. Studies 
in animals demonstrate that administration of com 
pound for a two week period reduces the level of oxi 
dized brain enzymes to normal and restores memory to 
the same level as tested in young control animals. A 
signi?cant reduction in oxidized proteins and memory 
recovery is observed as early as seven days after initia 
tion of treatment; levels are still comparable to young 
controls one to three days following cessation of treat 
ment, and partially reduced at seven days following 
cessation of treatment. 
These compositions and methods are useful in the 
treatment of age-related disorders, pre-surgical and/or 
pre-anesthetic preparation or administration of chemo 
therapeutic agents, and in treatment of disorders or 
trauma of the brain, cardiovascular system, lymphatic 
system, and, potentially, in the treatment of some viral 
disorders characterized by oxidation of host proteins in 
cells infected by the virus. 
BRIEF DESCRIPTION OF THE FIGURES 
FIG. 1 is a graph of the alkaline protease activity 
from gerbil cortex (% of young, three to four month old 
gerbil cortex) for young gerbils (age three to four 
months), old gerbils (retired breeders of twelve to ?f 
teen months of age), old gerbils that received twice 
daily injections of 0.1 ml saline/kg body weight, and old 
gerbils that received twice daily injections of 10 mg 
PBN in saline/kg body weight for two weeks. Protease 
activity was determined using oxidized protein ex 
tracted from young gerbil cerebral cortex. 
FIG. 2A and FIG. 2B are graphs comparing protein 
carbonyl activity (pmol/mg protein) (FIG. 2A) and 
glutamine synthetase activity (FIG. 2B) in the cerebral 
cortex (neocortex) of young adult and old gerbils over 
days of administration of 32 mg PBN/kg administered 
twice a day and assayed at one, three, seven or fourteen 
days. At the end of each of the days indicated, animals 
were decapitated and cerebral cortex removed and 
rapidly frozen in liquid nitrogen. Protein carbonyl con 
tent was determined using the DNPH procedure. The 
results demonstrate the reduction in oxidative damage 
to proteins and the loss of enzyme activity in gerbil 
cerebral cortex as a result of twice daily administration 
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of 32 mg PBN/kg (i.p.). Each histogram is the mean of 
three subjects. . 
FIGS. 3A, 3B and 3C are graphs comparing changes 
in protein carbonyl (pmol/mg protein) (FIG. 3A), glu 
tamine synthetase (FIG. 3B), and protease activity (% 
control) (FIG. 3C) over days following termination of 
twice daily dosing with 10 mg PBN/kg body weight. 
FIG. 3A represents the level of carbonyl in the soluble 
protein obtained from gerbils treated for fourteen days 
and tested at l, 3, 7 and 14 days post dosing. FIG. 3B is 
the time related decrease in cortical glutamine synthe 
tase (GS) activity after termination of twice daily injec 
tions of PBN. FIG. 3C demonstrates the‘ time related 
decrease in alkaline protease activity following termina 
tion of twice daily injections of PBN. Each histogram is 
the mean i standard error (SE) of three subjects at 
each of the indicated times. The asterisk and dashed line 
indicates the old gerbil, untreated control values for 
each of the measures. 
FIG. 4A, 4B and 4C are graphs comparing changes in 
protein carbonyl (pmol/mg protein) (FIG. 4A), gluta 
mine synthetase (FIG. 4B), and protease activity (% 
control) (FIG. 4C) over days following termination of 
twice daily dosing with 32 mg PBN/kg body weight. 
FIG. 4A represents the level of carbonyl in the soluble 
protein obtained from gerbils treated for fourteen days 
and tested at l, 3, 7 and 14 days post dosing. FIG. 4B is 
the time related decrease in cortical glutamine synthe 
tase (GS) activity after termination of twice daily injec 
tions of PBN. FIG. 4C demonstrates the time related 
decrease in alkaline protease activity following termina 
tion of twice daily injections of PBN. Each histogram is 
the mean t SE. of three subjects at each of the indi 
cated times. The asterisk and dashed line indicates the 
old gerbil, untreated control values for each of the mea 
sures. 
FIG. 5 is a graph of the eight arm radial arm maze 
performance of young or old gerbils treated with either 
saline or PBN. Gerbils were placed into the central 
compartment of the maze with the barrier in place to 
limit exploration. After the barrier was removed, the 
number of arms re-entered and the total elapsed time 
before all eight arms were entered was recorded. Each 
histogram represents the mean i- of 18 gerbils. The 
animals were administered PBN twice daily (either 10 
or 32 mg PBN/kg body weight) for seven'days and 
tested at the end of seven days of dosing. 
DETAILED DESCRIPTION OF THE 
INVENTION 
It has now been discovered that, further to the meth 
ods using PBN for the treatment and prevention of 
ischemic damage described and claimed in US. Ser. 
No. 07/422,651 ?led Oct. 17, 1989, spintrapping agents 
are useful in preventing or treating symptoms associ 
ated with aging, trauma, drug administration and sur 
gery, especially of the brain. As used herein, a free 
radical scavenger or spin-trap reagent is a molecule that 
will form a stable complex spin adduct spin-adduct of a 
carbon with a free radical. A free radical is a molecule 
in which the free radical is localized on a carbon atom. 
As a result of this chemical bond formation, the free 
radical is no longer damagingto the cell. In combina 
tion with a pharmaceutical vehicle suitable for adminis 
tration to a patient, preferably by oral administration, 
these compounds are useful in preventing or reversing 
symptoms associated with aging, for example, increased 
levels of oxidized proteins, decreased enzymatic activ 
5,405,874 
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ity, and loss in spatial and short term memory. Cur 
rently, there are no effective, non-toxic treatments for 
aging, Effectiveness has been demonstrated in animals 
after as few as seven days of administration. Effective 
ness continues for at least one week after administration. 
Values return to pretreatment levels after two weeks. 
Useful Spin-trapping compounds 
PBN and derivatives thereof 
The preferred spin-trapping compounds are a-phenyl 
t-butyl nitrone (PBN), and derivatives thereof. PBN has 
no measurable effect on normal or uninjured cells. PBN 
is the preferred compound at this time, although a num 
ber of derivatives are also useful, including hydroxy 
derivatives, especially 2-, 3- or 4-hydroxy PBN and 
mono-, di- and trihydroxy tert-butyl nitrone; esters, 
especially esters which release 2-, 3, or 4-hydroxyphe 
nyl t-butyl nitrone such as the acetoxy derivative, 2-, 3-, 
or 4-carboxyphenyl t-butyl nitrone, such as the ethyl 
derivative, or phenyl hydroxybutyl nitrone, such as the 
acetoxy derivative; alkoxyl derivatives, especially alk 
oxyl derivatives which release 2-, or 4-hydroxyphenyl 
t-butyl nitrone, such as the methyl derivative; and acet 
amide derivatives, especially acetamide derivatives 
which release 2-, or 4 aminophenyl t-butyl nitrone, such 
as the acetyl derivative; diphenyl nitrone (PPN) and the 
analogous diphenyl nitrone derivatives. As used herein, 
“PBN” refers to both phenyl t-butyl nitrone and deriva 
tives thereof, unless otherwise stated. 
The general formula for PBN and useful derivatives 
thereof is: 
H O 
C=N+ 
X Y 
wherein: 
X is phenyl or 
(01K)” 
wherein 
R is H, 
0 
Y 
and n is a whole integer from 1 to 5; or 
Y is a tert-butyl group that can be hydroxylated or 
acetylated on one or more positions; phenyl; or 
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OW 
wherein 
W is 
O 0 
ll II II 
c-cm, -NH—C—Z, c-oz, 
or Z; and 
Z is a C1 to C5 straight or branched alkyl group. 
Other spin-trapping reagents 
Other spin-trapping agents can also be used, such as 
5,5-dimethyl pyrroline N-oxide (DMPO) or a-(4-pyri 
dyl 1-oxide)-N-tertbutylnitrone (POBN), and spin-trap 
ping derivatives thereof. Derivatives are made using 
standard techniques, for example, for substitution of the ' 
methyl groups.The general formula for DMPO is: 
so 
B i 
0 
wherein 
A and B are independently CH3, CHZOH, CHZOW, 
or 
(OWL, 
n is an integer from 1 to 5 
wherein 
W is 
O 0 
II II II 
—C—CH3, —NH--C—Z, —c—0Z, 
or Z ; and 
Z is a C1 to C5 straight or branched alkyl group. 
The general formula for POBN is: 
O 
i 
wherein 
Y is a tert-butyl group that can be hydroxylated or 
acetylated on one or more positions; phenyl; or 
5,405,874 
n is a whole number from 1 to 4, or 
Z is a C1 to C5 straight or branched alkyl group. 
Indications that the compositions are useful in treating 
The free-radical scavenger compositions are useful in 
treating a variety of dysfunctions or disorders charac 
terized by oxidized proteins in the tissues or cells. Oxi 
dation of cytosolic protein has been demonstrated to 
occur in a wide variety of pathological conditions. dAc 
cordingly, compounds which have as their fundamental 
mechanism of action the interference of production of 
oxidized protein should be useful in the treatment of a 
wide variety of diseases having what appears at ?rst 
glance to be widely dissimilar etiologies, because the 
fundamental cause of the condition is oxidation of pro 
tein or nucleic acids. 
In one embodiment, the spin-trapping agent is admin 
istered to a patient to reverse the damage occurring as a 
function of age. Preliminary results indicate that there is 
a net increase in the oxidation of proteins and the accu 
mulation of oxidized material in the brain. The develop 
ment of senil plaque is also routinely observed in aged 
patients. 
Other disorders are those resulting from trauma, such 
as a blow to the head, or from drug treatment, for exam 
ple, administration of anesthesia or drug abuse, or even 
as a result of some types of viral infections. 
It has now been determined that the level of oxidized 
brain protein appears to be inversely related to perfor 
mance in a short term memory task and directly related 
to risk of stroke-induced damage and behavioral 
change. Increased cellular oxidation may result in one 
or more of the following: (a) oxidative damage to cellu 
lar proteins could cause a change in the regulation of 
ion channels, there could be a change in the rate and 
ef?ciency of signal translation and membrane depolar 
ization, signi?cant changes in energy ?uxes may occur 
and compromise selective function, the ?delity of RNA 
transcription may be altered due to oxidative damage to 
DNA, RNA translation may be affected either by oxi 
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dation of the RNA or regulatory macromolecules, or 
the rate of protein degradation may be altered. 
Any of these changes could negatively impact on the 
acquisition consolidation and retrieval of information, 
even by interference with a single step in the learning 
and memory process. It is possible that oxidation of cells 
in a particular brain region could result in acquisition 
de?cits, whereas oxidation of a different region could 
result in output de?ciency. Considering the number of 
devastating neurodegenerative diseases, including Alz 
heimer’s disease, this treatment could potentially be a 
tremendous help to people with these disorders. 
Examples of other disorders that can be treated with 
these compositions include peripheral neuropathy of 
diabetes, exercise induced muscle damage and pain, and 
enhancement of cellular response to hormonal signals. 
Treatment of neurodegenerative disorders 
Several neurodegenerative conditions are most ap 
propriately treated by compounds that interfere with 
protein oxidation. Alzheimer’s disease has been associ 
ated with the accumulation of abnormal oxidized prote 
ins or the production of abnormal proteins in areas that 
are pathologically affected. In addition, age related 
enhancement in protein oxidation occurs in all cells in 
the aged individual. PBN and derivatives thereof have 
been demonstrated to be useful in the reduction in pro 
tein oxidation and in the increase in the activity of criti 
cal enzymes within the brain of aged animals. Since this 
is a fundamental change in oxidative state, it is likely 
that PBN and other related compounds would be useful 
when given chronically to individuals who are in the 
early phases, or possibly in the late phases, of Alzhei 
mer’s disease. In addition, multiinfarct dementias should 
be treatable with these compounds, since they also deal 
with ischemia reperfusion oxidation issues. 
Senile dementia has not been directly evaluated for 
ischemia reperfusion etiology or protein oxidation, 
however, it is likely that senile dementia would also be 
treatable with these compounds. This is based on the 
hypothesis that advanced age is associated with in 
creased production of oxidized protein. In progeria, a 
unique condition in which aging is accelerated, Stadt 
man and colleagues at the NIH have demonstrated that 
there is a marked increase in the base-level of oxidized 
protein even in young adult subjects with progeria, as 
reported by Oliver, et al., J. Biol. Chem. 262, 5488-5491 
(1987) and Starke-Reed and Oliver, Arch. Biochem. 
Biophys. 275, 559-567 (1989). While this is a rare condi 
tion it should also be treatable with these compositions. 
Another condition which is likely to be associated 
with oxidative damage arising from microcirculatory ' 
difficulties is the diabetic peripheral neuropathies and 
vascular change. These are tragic conditions in which 
amputation is eventually necessary in order to save the 
patient. While these compounds are not likely to im 
prove vascular flow they are likely to reduce the impact 
of transient changes in vascular flow which result in 
oxidation and damage to the peripheral nerves and also 
in damage to the skeletal muscle which is often associ 
ated with the condition called exercise induced or inter 
mittent claudication. If the retinopathy associated with 
diabetes is also an ischemia reperfusion microcirculation 
problem, then the spin-trapping compounds will be 
useful in treating the retinal damage which occurs very 
frequently in diabetic patients. 
5,405,874 
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Pre-surgical preparation 
Since the status of the cell and its survival in a hyp 
oxic or anoxic environment is dependent upon the abil 
ity of the cell to compartmentalize metals and handle 
oxygen in a useful manner, in contrast to peroxidation, 
it is expected that these compounds will be useful as 
presurgical preparatory medication to reduce the car 
bonyl load and improve the enzyme status of the patient 
prior to elective surgery. These compounds would also 
help the cells of the body achieve a higher level of 
enzymatic function, shorten the recuperative phase, and 
reduce the likelihood of any interoperative complica 
tions associated with changes in microcirculation. 
Treatment of viral infections and in?ammatory 
disorders 
Retroviruses selectively infect certain types of cells, 
such as lymphocytes. An example of a retrovirus that 
has been the subject of much research activity is the 
human immunode?ciency virus (HIV), which causes 
Acquired Immunode?ciency Syndrome (AIDS). No 
means for prevention of infection has been found, al 
though there have been numerous attempts to ?nd a 
treatment. Since activation of lymphocytes is associated 
with the oxidation of protein and activation of lympho 
cytes is required prior to release of newly formed vi 
ruses, it is expected that administration of these compo 
sitions will inhibit infection and replication of lympho 
cytes by the viruses. The activation of the T4 lympho 
cyte is associated with a cascade of biochemical intra 
cellular changes, one of which is the production of 
oxidized protein. If PBN and/or related compounds can 
block protein oxidation in the abnormal process then it 
is possible that PBN or other spin-trapping compounds 
could in fact interfere with the process of viral replica 
tion and/or dissemination of the virus from the host cell 
(T —4 lymphocyte), thereby acting as a virustatic agent 
by preventing the T4 lymphocyte from releasing the 
newly formed viruses. This would be analogous to the 
use of isoniazid (INH) in the treatment of tuberculosis. 
At low doses INH is a tubercula static in that it reduced 
the infectivity and spread of the tuberculosis, thereby 
effectively protecting the patient from pulmonary dam 
age. 
It is important to note that the effects of the spin-trap~ 
ping compounds occur in animals that have a base-level 
of carbonyl formation which appears to be necessary 
for post translational processes. Old animals have a 
signi?cantly elevated level of carbonyl protein which is 
associated with decreased enzymatic function relative 
to young control animals. When young control animals 
are given the exact same dosage regimen, there is no 
signi?cant change in enzyme activity nor is there signif 
icant change in protein carbonyl. Thus the PBN and 
related spin-trapping compounds are not likely to inter 
fere with fundamental processes that are necessary for 
the normal cellular function. 
In conclusion, a number of clinical conditions appear 
to have as their fundamental cause oxidation of cellular 
protein and enzymatic damage. Spin-trapping com 
pounds are effective in animal models in reducing the 
protein oxidation and improving enzymatic function. 
This occurs in preparations in which the abnormal oxi 
dized protein is modi?ed and protected but the normal 
post translational oxidation is allowed to occur. This 
would suggest that PBN does not interfere with the 
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normal necessary oxidation of proteins following syn 
thesis. 
Effective dosages of PBN. 
Exemplary dosages of PBN range from 0.1 to 10 
mg/kg of body weight in animals. The effective dosage 
of PBN in humans is expected to be between approxi 
mately 1 and 10 mg/70 kg body weight. Toxicity tests 
have demonstrated that the compound is completely 
innocuous, with such low toxicity that it was not possi 
ble to determine an LDS‘Q. 
In the preferred application, the PBN is administered 
to a patient suffering from memory loss or other symp 
toms frequently associated with aging. Optimum results 
are generally observed after two weeks of daily or 
twice daily oral administration. The compositions can 
also be effectively administered prior to, during or 
shortly after surgery, and prevent or decrease the extent 
of cellular damage resulting from either the trauma or 
anesthesia. 
Since the trapping of endogenous free radicals is 
speci?c for only those cells that have been exposed to 
the conditions that result in the production of free radi 
cals, the traps have little or no effect on normal cells. 
The bene?cial effects occur only in injured cells, and do 
not require the presence of speci?c receptors, speci?c 
enzymes, and/or speci?c cell types. 
Methods of administration of PBN 
The PBN is preferably administered systemically, 
most preferably orally, since this is the most rapid and 
ef?cient means for delivering the active compound to 
the site of free radical generation. The PBN may be 
administered at once, or may be divided into a number 
of smaller doses to be administered at varying intervals 
of time. Other methods of administration can also be 
used, including subcutaneous, intravenous, and intra 
peritoneal administration. The concentration of active 
compound in the drug composition will depend on 
absorption, inactivation, and excretion rates of the drug 
as well as other factors known to those skilled in the art. 
The effective dosage may also be determined based on 
that amount required to prevent or reverse predisposi 
tion of the cells to damage resulting from depletion of 
ATP (as demonstrated by in vivo NMR) and damage 
from free radical generation. It is to be noted that dos 
age values will also vary with the condition of the pa 
tient being treated. It is to be further understood that for 
any particular subject, specific dosage regimens should 
be adjusted over time according to the individual need 
and the professional judgment of the person administer 
ing or supervising the administration of the composi 
tions, and that the concentration ranges set forth herein 
are exemplary only and are not intended to limit the 
scope or practice of the claimed composition. 
A preferred mode of administration of the active 
compound is in a form for oral delivery. Oral composi-‘ 
tions will generally include an inert diluent or an edible 
carrier. Preferred pharmaceutical carriers for intrave 
nous administration are saline or phosphate buffered 
saline at physiological pH. Since PBN degrades at pH 
less than approximately 3 to 4, it is preferred to adminis 
ter the PBN at a pH of 4 or higher, or in combination 
with food, a buffering agent, or in an enteric coating. 
For oral delivery, the PBN may be enclosed in capsules, 
compressed into tablets, microencapsulated, entrapped 
in liposomes, in solution or suspension,alone or in com 
bination with a substrate immobilizing material such as 
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starch or poorly absorbable salts such as immodium. 
Pharmaceutically compatible binding agents can be 
included as part of the composition. The tablets or cap 
sules may contain, for example, any of the following 
ingredients, or compounds of a similar nature: a binder 
such as microcrystalline cellulose, gum tragacanth or 
gelatin; an excipient such as starch or lactose, a disinte 
grating agent such as alginic acid, Primogel ®, or corn 
starch; a lubricant such as magnesium stearate or Ste 
rotes; a gildant such as colloidal silicon dioxide; a sweet 
ening agent such as sucrose or saccharin; or a ?avoring 
agent such as peppermint, methyl salicylate, or orange 
?avoring. When the dosage unit form is a capsule, it can 
contain, in addition to material of the above type, a 
liquid carrier. In addition, dosage unit forms can contain 
various other materials which modify the physical form 
of the dosageunit, for example, coatings of sugar, shel 
lac, or other enteric agents. 
The present invention- will be further understood 
with reference to the following non-limiting examples 
demonstrating methods for determining effectiveness of 
PBN administration for treatment or prevention and/ or 
reversal of symptoms associated with aging. 
Example 1 
Determination of brain enzyme levels in old versus 
young gerbils treated with PBN 
A correlations between the duration of ischemia and 
either the change in spontaneous behavior or the level 
of oxidized brain protein has previously been demon 
strated in gerbils. Many other psychiatric and neurolog 
ical conditions have been proposed to be the result of 
oxidation. Among these conditions, cellular aging has 
been associated with oxygen radicals and the accumula 
tion of proteins. The level of oxidized protein, gluta 
mine synthetase activity, brain protease activity and 
radial arm maze performance in young adult and retired 
breeder gerbils have now been compared and demon 
strate that there is a direct relationship between the age 
of the subject and the level of oxidized brain protein, as 
measured using a protein carbonyl assay. Increased 
levels of protein carbonyl were associated with de 
creased glutamine synthetase activity and decreased 
alkaline protease activity. In contrast, there was no 
change in acid protease activity of retired breeders, 
compared to young adult gerbils. Consistent with the 
age-related increase in protein oxidation and enzyme 
damage, retired gerbils made signi?cantly greater num 
bers of errors in a test of short-term memory, compared 
to young adult gerbils. These studies demonstrate that 
the functional de?cits that occur as a result of aging 
may be associated with increased protein oxidation and 
decreased brain enzyme activities. 
This system has been used to demonstrate the effec 
tiveness of PBN in restoring young brain enzyme levels 
and short term memory to old animals. The results are 
shown in FIGS. 1 through 5, as follows. Young gerbils 
were obtained from Tumblebrook Farms, West Brook 
?eld, Mass, weighing 50-60 grams and age three to 
four months. Control gerbils were given saline. Animals 
were killed by decapitation and their brains removed 
for analysis. 
FIG. 1A is a graph of the percent alkaline protease in 
young (three to four month old) gerbils, old (twelve to 
?fteen month old retired breeder) gerbils, old gerbils 
administered 0.1 ml saline twice daily (b.i.d.), and old 
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gerbils administered 10 mg PBN/kg body weight b.i.d. 
for fourteen days. 
The results demonstrate that PBN is effective in re 
storing alkaline protease levels in old animals to those 
levels present in young animals. 
FIG. 2A is a graph of the changes in protein oxida 
tion from brains of young and senescent gerbils, plotting 
nmol protein carbonyl/mg protein versus days of treat 
ment with PBN. The gerbils were given twice daily 
injections of 32 mg/kg PBN for fourteen days. Animals 
were killed at one, three, seven and fourteen days and 
protein carbonyl levels determined. 
As can be seen in the ?gure, there is no change in the 
level of oxidized protein of young gerbils treated for up 
to 14 days with PBN. This indicates that the level of 
oxidized protein is likely to be a natural and necessary 
post translational effect, for example, if after synthesis 
of the protein, the protein is activated by a modi?cation 
involving carbonyl oxidation. In contrast to the car 
bonyl level seen in young animals, control aged animals 
(15 months of age) have a marked increase of carbonyl 
content. This increased carbonyl content is responsive 
to treatment with PBN. Multiple days of treatment with 
PBN results in a progressive reduction in the level of 
protein carbonyl to the level seen in young animals. 
The level of protein carbonyl reduction (oxidized 
protein burden of neurons in the brain) is only to the 
level of the normal young gerbil brain. Neither the 
levels in the young gerbil brain nor the levels in the 
senescent gerbil brain can be further reduced beyond 
this level. This observation supports the hypothesis that 
there is a necessary level of oxidation that occurs in 
cells in normal animals, which is required for cells to 
have “normal function”, and that control aged animals 
(15 months of age) have a marked increase of carbonyl 
content. This increased carbonyl content is responsive 
to treatment with PBN. The ability of PBN to reduce 
the protein carbonyl load of cells also indicates that this 
is an active oxidation process which occurs at a regular 
or predictable rate and that there are mechanisms exis 
tent within the cells of the brain which can remove this 
oxidized protein if the process is interrupted. 
FIG. 2B compares the levels of glutamine synthetase 
(gs) in young and old animals and evaluates the effects 
of daily administration of PBN on the speci?c activity 
of the enzyme. This particular enzymatic marker has 
been selected because it is a highly sensitive protein to 
oxidation and because it is a metalloprotein that has 
bound to it metal which may participate in the genera 
tion of free radicals if the metal is dissociated with its 
binding site. Glutamine synthetase activity has been 
used by Stadman and colleagues (Oliver, et al., Proc. 
Natl, Acad. Scie. USA 87, 5144-5147 (July 1990)) as a 
marker enzyme for alterations following protein oxida 
tion. 
As shown in FIG. 2B, the level of glutamine synthe 
_ tase is lower in old gerbils (1.2) than in young adult 
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gerbils (2.1). This is consistent with previous studies in 
which increases in the level of the carbonyl protein 
(oxidized protein in cells) is associated with a decrease 
in glutamine synthetase activity. In particular, if the 
glutamine synthetase enzyme is puri?ed and the car 
bonyl content of that enzyme is evaluated, there is a 
marked increase in the level of oxidized protein in the 
presence of lowered glutamine synthetase activity. As 
also demonstrated in FIG. 2B, repeated administration 
of PBN in young gerbils had no effect on glutamine 
synthetase activity, providing further evidence that the 
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level of carbonyl is associated with normal function and 
chronic administration of PBN has no effect on either 
the level of carbonyl or on the marker enzyme activity. 
In contrast to the young gerbils, old gerbils given daily 
injections of PBN show a time related increase in gluta 
mine synthetase activity that parallels the reduction in 
protein carbonyl content, indicating that the reduction 
in oxidized protein burden of cells is associated with a 
recovery of the enzymatic activity to the normal level 
seen in young adult gerbils. 
It is important to note that there is no increase in 
enzymatic activity above that seen in young adult ger 
bils. Thus the treatment with PBN reverses the effect of 
aging on enzymatic activity but does not result in an 
activation of enzyme activity that exceeds the normal 
values. 
Example 2 
Determination of residual effect of PBN on reduction of 
brain enzyme levels 
As shown in FIGS. 3A, 3B, and 3C, as compared 
with FIGS. 4A, 4B, and 4C, administration of 10 mg 
PBN/kg is as effective as administration of 32 mg 
PBn/kg body weight in restoring young enzyme levels. 
The appropriate dosages and full range of effective 
dosages for other species of animals can be determined 
using a similar methodology. 
The time related changes in protein oxidation and 
enzyme activity following termination of twice daily 
dosing with either 10 mg PBN/kg (FIGS. 3A, B, and C) 
or 32 mg PBN/kg (FIGS. 4A, B, and C) are also shown 
by these ?gures. The results demonstrate that the effect 
of the PBN is unaltered one to three days after termina 
tion of treatment twice daily with the PBN, although 
the PBN itself has a half-life of three hours. At seven 
days, the enzyme levels are altered by approximately 
50%. At fourteen days, the oxidized enzymes have 
returned to approximately their pre-treatment levels. 
Example 3 
Demonstration of correlation between effect of PBN on 
brain enzymes and memory 
FIG. 5 demonstrates that there is a functional coun 
terpart to such treatment. Young and old gerbils were 
tested in a radial arm maze test for spacial and short 
term memory. Animals were placed in the central hub 
of a eight armed radial maze and given access to explore 
all eight arms of the radial arm maze. When the animal 
completed the test of exploring each of the eight arms, 
the animal was removed from the maze. The number of 
times that the animals reentered arms that had been 
previously entered was counted as an error. Under ideal 
conditions animals will enter each one of the eight arms 
but not reenter any of the arms. In many cases young 
adult gerbils (young) entered each of the arms without 
reentering any of the arms. The time required to enter 
all eight arms was also recorded but did not appear to 
determine'the ef?ciency of the short term memory task. 
As can be seen in FIG. 6, young gerbils made an aver 
age of 2.83 errors during the test session. In contrast. old 
gerbils made an average of 6.82 errors, which is a highly 
signi?cant difference between the two groups. 
Young adult gerbils exposed to a period of transient 
ischemia, which is also an oxidizing process, make a 
substantial number of errors with an average value of 15 
errors in such a test session. During the post ischemic 
period, there is a marked build up of carbonyl protein 
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and reduction in glutamine synthetase activity similar to 
that which is seen in aging. 
Treatment of gerbils for seven days results in a 
marked alteration in the number of errors seen with old 
gerbils. Young gerbils given PBN for seven days were 
not signi?cantly different from control gerbils whereas 
the old gerbils given PBN for seven days showed a 
marked reduction in the number of errors and returned 
to the range of performance seen with control young 
gerbils. Thus, there is a functional counterpart to the 
biochemical changes that are seen in that reduction in 
protein carbonyl and the increase in glutamine synthe 
tase activity following chronic PBN treatment. This 
functional counterpart is demonstrated by the number 
of errors seen in a short term spacial memory task, the 
radial arm maze. It should be noted that the radial arm 
maze test does not require any food reinforcement or 
any other reward associated with the' test. Naive ani 
mals are placed into the radial arm maze, are tested once 
and these differences are reliable on retest. 
Modi?cations and variations of the method and com 
position for the treatment of aging will be obvious to 
those skilled in the art from the foregoing detailed de 
scription. Such modi?cations and variations are in 
tended to come within the scope of the appended 
claims. 
We claim: 
1. A method of improving short term memory in a 
patient suffering from short term memory loss compris 
ing administering to said patient an effective amount of 
a composition capable of improving short term mem 
ory, said composition having as the active ingredient a 
compound selected from the group consisting of a-phe 
nyl t-butyl nitrone (PBN) and derivatives thereof se 
lected from the group consisting of hydroxy PBNs, 
PBN esters, acetoxy PBNs, alkyl PBNs, alkoxy PBNs, 
and phenyl PBNs having spin trapping activity; and a 
pharmaceutically acceptable carrier therefor. 
2. The method of claim 1 wherein the active agent is 
a spin-trapping derivative of PBN having the formula: 
H O 
C=N+ 
X Y 
wherein: 
X is phenyl or 
(0K)” 
wherein 
R is H, 
0 
II / 
Z—C—, or Z; or —CH=N , 
\ 
Y 
and n is a whole integer from 1 to 5; or 
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o H o- (I) 
NH—g-Z; C=N+ 
5 X Y 
Y is a tert-butyl group that can be hydroxylated or Whe1'_ein¢ 
acetylated on one or more positions; phenyl; or X 15 phenyl or 
i 10 
ow (011)” 
15 
wherein wherein 
W is R is H, 
20 O 0 
II II II II _ / 
C—CH3, NH-C-Z, C-.-OZ, _‘Z_C", 01‘ Z; Or _CH—N+\ , 
Y 
or Z; and 
Z is a C1 to C5 straight or branched alkyl group. 25 and n is a whole integer from 1 to 5; or 
3. The method of claim 1 wherein the active ingredi 
ent is a-phenyl t-butyl nitrone. 
4. The method of claim 1 wherein the PBN or deriva 
tives thereof is provided in a dosage of between 1 and 
300 mg/kg body weight. 
5. The method of claim 4 wherein the PBN or deriva 
tives thereof is provided in a dosage of between 1 and 10 
mg/kg body weight. 
6. The method of claim 1 wherein the active agent is 
provided in combination with a pharmaceutical carrier 
selected from the group consisting of microspheres, 
liposomes, immobilizing substrates, polymeric matrices 
and buffering agents. 
7. The method of claim 1 wherein the short term 
memory loss is associated with ischemia and wherein 
the route of administering is intravenous. 
8. The method of claim 1 wherein the short term 
memory loss is associated with progressive neuronal 
loss and wherein the route of administering is oral. 
9. The method of claim 8 wherein the progressive 
neuronal loss is due to Parkinson’s disease. 
10. The method of claim 8 wherein the progressive 
neuronal loss is due to senile dementia. 
11. The method of claim 8 wherein the progressive 
neuronal loss is due to Alzheimer’s disease. 
12. The method of claim 1 wherein X is 
30 
35 
45 
55 
(011)” 
v 
and R is H or Z. 60 
13. The method of claim 12 wherein Y is a tert-butyl 
group. 
14. A method for improving short term memory in a 
patient suffering from short term memory loss compris- 65 
ing administering to said patient an effective amount of 
a compound selected from ' 
(a) at least one compound of formula (I): 
Y is a tert-butyl group that can be hydroxylated or 
acetylated on one or more positions; phenyl; or 
OW 
wherein 
W is 
O O 0 
II II II 
0-01-13, NH-C-Z, c-oz, 
or Z; and 
Z is a C1 to C5 straight or branched alkyl group; or 
(b) at least one other alpha-phenyl t-butyl nitrone 
(PBN) derivative selected from the group consist 
ing of hydroxy PBNs, PBN esters, acetoxy PBNs, 
alkyl PBNs, alkoxy PBNs and phenyl PBNs having 
spin-trapping activity in vivo in tissue, 
optionally in association with a pharmaceutically 
acceptable carrier. 
15. A method according to claim 14 wherein said 
compound is provided in combination with a pharma 
ceutical carrier. 
16. A method according to claim 14 wherein said 
compound is provided in combination with a pharma 
ceutical carrier selected from the group consisting of 
microspheres, liposomes, immobilizing substrates, poly 
meric matrices, and buffering agents. 
17. A method according to claim 14 wherein said 
compound is administered in a dosage of from 1 to 300 
mg/kg body weight. 
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18. A method according to claim 14 wherein said 
compound is administered in a dosage of from 1 to 10 
mg/kg body weight. 
19. The method of claim 14 wherein the short term 
memory loss is associated with ischemia. 
20. The method of claim 14 wherein the short term 
memory loss is associated with progressive neuronal 
loss. 
21. The method of claim 20 wherein the progressive 
neuronal loss is due to Parkinson’s disease. 
22. The method of claim 20 wherein the progressive 
neuronal loss is due to senile dementia. 
23. The method of claim 20 wherein the progressive 
neuronal loss is due to Alzheimer’s disease. 15 
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24. The method of claim 14 wherein Y is tert-butyl. 
25. The method of claim 14 wherein X is 
and R is H or Z. 
26. The method of claim 25 wherein Y is tert-butyl. 
27. The method of claim 25 wherein R is H. 
28. The method of claim 25 wherein R is Z. 
29. The method of claim 14 wherein when Y is tert 
butyl then X is not phenyl. 
* * * * * 
